Collaboration Revenue was Kura Oncology’s largest product and service line in fiscal 2025, bringing in $65.35M of $67.48M (97%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Collaboration Revenue | $53.88M | $65.35M |
| Product Revenue, Net | — | $2.13M |
| Total | $53.88M | $67.48M |
Kura Oncology brought in $67.48M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Kura Oncology regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $53.88M. Collaboration Revenue was the largest at $65.35M (96.8%), ahead of Product Revenue, Net at $2.13M (3.2%).
Kura Oncology began breaking out Product Revenue, Net in fiscal 2025, when it brought in $2.13M.
Kura Oncology (KURA) reports its revenue by product and service. In fiscal 2025, Collaboration Revenue was its largest product and service line, bringing in $65.35M (96.8% of the total), followed by Product Revenue, Net at $2.13M (3.2%).
Collaboration Revenue was Kura Oncology's largest product and service line in fiscal 2025, bringing in $65.35M, or 96.8% of the $67.48M total across its two product and service lines.
Every figure comes from Kura Oncology's annual financial filings, as reported. Each line keeps the name Kura Oncology gives it, and years follow its fiscal calendar.
Kura Oncology's revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.